Good question. I wonder if you could move a few indications through under one Phase 1 trial. Its really to assess pk's and adverse effects so there may be some indications that could be grouped I imagine?
If you have safety data from covid phase1, mnd phase1, the old Adelaide hospital cancer phase 1, would we then need a full phase 1 for future indications. I imagine there is a cost element too where a cheaper phase 1 will determine whether you bother with a more costly phase 2.
Ann: Preliminary MPL antiviral leukaemia preclinical WEHI results, page-36
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $99.71M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $66.86K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27750 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 84999 | 3 |
View Market Depth
| Last trade - 14.42pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |